Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses treatment strategies for patients with FLT3-mutated acute myeloid leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT). She mentions that treatment with FLT3 inhibitors should be continued prior to and after alloSCT to prevent relapse, as evidenced in the QuANTUM-First study (NCT02668653). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
